Stockscreener 앱 받기
1.05
0.00%
0.01
전일 마감가:
$1.06
열려 있는:
$1.05
하루 거래량:
198.77K
Relative Volume:
0.55
시가총액:
$12.51M
수익:
$10.72M
순이익/손실:
$-39.71M
주가수익비율:
-0.0675
EPS:
-15.5542
순현금흐름:
$-32.21M
1주 성능:
+14.53%
1개월 성능:
+6.52%
6개월 성능:
-70.72%
1년 성능:
-89.16%
1일 변동 폭
$1.045
$1.10
1주일 범위
$0.9302
$1.10
52주 변동 폭
$0.8435
$21.60
재규어 헬스 Stock (JAGX) Company Profile
명칭
Jaguar Health Inc
전화
415-371-8300
주소
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
JAGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
1.05 | 12.51M | 10.72M | -39.71M | -32.21M | -6.9342 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.14 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
713.97 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.93 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.91 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.26 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
재규어 헬스 Stock (JAGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
재규어 헬스 주식(JAGX)의 최신 뉴스
Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Earnings Call Transcript - MSN
FDA approves orphan-drug designation for Jaguar Health’s cholera drug, Crofelemer - MSN
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications - Barchart
Jaguar Health's Magdalena JV Imports 6kg of Coca Leaf for Novel Mental Health Drug Development - StockTitan
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder - Corsicana Daily Sun
Jaguar Health Launches Phase 2 Trial for Rare Pediatric Disease Treatment with Orphan Drug Status - StockTitan
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera - Eagle-Tribune
Jaguar Health Secures FDA Orphan Drug Status for Groundbreaking Cholera Treatment - StockTitan
Jaguar Health stock plunges to 52-week low of $0.87 By Investing.com - Investing.com Canada
Jaguar Health stock plunges to 52-week low of $0.87 - Investing.com
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES - Quantisnow
Jaguar Health Advances 5 Clinical Trials for Rare Disease Drug Crofelemer, Unveils Development Roadmap - StockTitan
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer - Yahoo Finance
JAGXJaguar Health, Inc. Latest Stock News & Market Updates - StockTitan
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) - AccessWire
Jaguar Health's Phase 3 Trial Shows Breakthrough Results for Cancer Therapy Diarrhea Treatment - StockTitan
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) - Corsicana Daily Sun
Jaguar Health to Present Promising Breast Cancer Treatment Data at Major Symposium - StockTitan
Jaguar Health Launches Major Clinical Trial for Orphan Drug Crofelemer in Short Bowel Syndrome - StockTitan
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins - Yahoo Finance
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine - Corsicana Daily Sun
Botanical and Plant-Derived Drugs Market to grow by USD 20.93 Billion (2024-2028), driven by government initiatives, with AI powering market evolutionTechnavio - The Malaysian Reserve
Jaguar Health Targets 6M Annual Cases With Novel Dog Diarrhea Drug NP300 - StockTitan
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference - AccessWire
Jaguar Health CEO to Present at NobleCon20 and Emerging Growth Conference | JAGX Stock News - StockTitan
Jaguar Health seeking partner to develop, commercialize NP300 - TipRanks
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs - WSIL TV
Jaguar Health Seeks Partner for Novel Dog Diarrhea Drug Targeting 6M Annual Cases | JAGX Stock News - StockTitan
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the YearEurope” - AccessWire
Napo Therapeutics Wins 'Best Pharma Innovator' Award, Advances Rare Disease Drug Trials | JAGX Stock News - StockTitan
Earnings call: Jaguar Health reports revenue growth in Q3 2024 By Investing.com - Investing.com Nigeria
Earnings call: Jaguar Health reports revenue growth in Q3 2024 - Investing.com
Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Jaguar Health extends agreement with financial managers - Investing.com India
Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Jaguar Health Sees Revenue Growth with New Product Launches - TipRanks
Jaguar Health extends agreement with financial managers By Investing.com - Investing.com UK
Jaguar Health reports Q3 EPS ($1.05) vs. ($22.50) last year - TipRanks
Jaguar Health Reports Third Quarter 2024 Financial Results - Yahoo Finance
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - Bluefield Daily Telegraph
Jaguar Health (JAGX) Sets Q3 2024 Earnings Call: Key Financial Updates Coming - StockTitan
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27% - Simply Wall St
Jaguar Health stock hits 52-week low at $0.93 amid challenges By Investing.com - Investing.com South Africa
Jaguar Health stock hits 52-week low at $0.93 amid challenges - Investing.com India
재규어 헬스 (JAGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.37%
0.73%
자본화:
|
볼륨(24시간):